Clinical Study

Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial

Table 2

Most common adverse events.

Most common AEsTTXPlacebo

Nausea68% (10% severe)23% (2% severe)
Dizziness61% (4% severe)18% (0% severe)
Oral hypoesthesia61% (0% severe)9% (0% severe)
Hypoesthesia48% (0% severe)10% (0% severe)
Oral paresthesia44% (0% severe)2% (0% severe)
Vomiting34% (3% severe)8% (0% severe)
Injection site irritation52% (6% severe)53% (7% severe)
Serious adverse events ()6 patients3 patients
SAEs related to TTX (after unblinding)5 events from 3 subjects: ataxia (2), neurotoxicity (1), nystagmus (1), and aspiration pneumonia (1)ā€‰

Statistical analyses of safety endpoints were descriptive only.